


Product Name : TAK-279
Cat. No. : PC-20516
CAS No. : 2272904-53-5
Molecular Formula : C₂₃H₂₄N₈O₃
Molecular Weight : 460.50
Target : JAK
Solubility : 10 mM in DMSO



Biological Activity

TAK-279 (Zasocitinib, NDI-034858) is a potent, selective and allosteric **TYK2** inhibitor, targets TYK2 JH2 domain with binding KD of 3.8 pM.

TAK-279 exhibits highly potent cellular pSTAT4 IL12 PBMC IC₅₀ of 6.7 nM.

TAK-279 displays functional selectivity over JAK1, JAK2, and JAK3.

TAK-279 inhibits IFN α -stimulated phosphorylation of STAT3 in CD3-positive T-cells as well as IFN α -stimulated CXCL10 production in whole blood with IC₅₀s of 1.7 and 22 nM, respectively.

TAK-279 inhibits IL23-stimulated phosphorylation of STAT3 in human CD161 + CD3 + TH17 cells with an IC₅₀ of 3.7 nM.

TAK-279 inhibits IFN α -stimulated CXCL10 production in mouse and rat whole blood with IC₅₀ of 347 and 91 nM, respectively.

TAK-279 also inhibits IL12-IL18-stimulated induction of IFN γ in whole blood with IC₅₀ of 48 nM.

TAK-279 (30 mg/kg) demonstrated dose-dependent suppression of IL12/IL18-induced IFN γ production in rat in vivo PD model.

References

- Patent WO2019023468 A1. Pyrazolopyrimidines as TYK2 inhibitors and their preparation.
- Leit S, et al. *J Med Chem*. 2023 Jul 10. doi: 10.1021/acs.jmedchem.3c00600.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com